HOME > TOP STORIES
TOP STORIES
-
REGULATORY Advisory Panel Shelves Decision on Avigan, Says No Clear Efficacy Shown for COVID-19
December 22, 2020
-
ORGANIZATION 3 Indicted Wholesalers Now Barred from National Hospital Organization Bids, Others Following Suit
December 21, 2020
-
REGULATORY Japan Saves 431.5 Billion Yen in Drug Price Cuts, Curbs Social Security Costs: FY2021 Draft Budget
December 21, 2020
-
BUSINESS Decision on Pfizer Vaccine Unlikely to Come before Japan Data Submission Slated by February
December 21, 2020
-
BUSINESS Pfizer/BioNTech’s COVID-19 Vaccine Filed in Japan, Exceptional OK Eyed
December 18, 2020
-
BUSINESS 5%-Plus Discrepancy Threshold for Off-Year Re-Pricing Draws Fire from Pharma, Wholesalers
December 18, 2020
-
REGULATORY Ministers Agree on 5%-Plus Price Discrepancy Line for Off-Year Re-Pricing; 59% Coverage for Innovative Meds, 88% for LLPs, 83% for Gx
December 18, 2020
-
REGULATORY Govt Settles on Discrepancy Rate Threshold of “Above 5%” for Off-Year Drug Re-Pricing, 430 Billion Yen Reduction, 60% Coverage for Innovative Meds
December 17, 2020
-
REGULATORY Japan Govt Eyes 4-6% Price Discrepancy Threshold for Off-Year Drug Re-Pricing
December 16, 2020
-
BUSINESS UCB Japan to Independently Market New Products; Stand-Alone E Keppra Sales “Going Smoothly”: President
December 16, 2020
-
REGULATORY Japan Weighs Drug Cost Cut of around 400 Billion Yen in Off-Year Re-Pricing, Expanded Coverage Including Products with Smaller-than-Average Price Gap Too
December 15, 2020
-
BUSINESS Forxiga Filed for Chronic Kidney Disease in Japan: AZ
December 15, 2020
-
BUSINESS 1st Death Reported for Kobayashi Kako’s Tainted Itraconazole Product
December 14, 2020
-
REGULATORY MHLW Unveils Overview of COVID-19 Vaccine Distribution Scheme in Japan
December 11, 2020
-
BUSINESS Boehringer Speeding Up Growth of Jardiance on Organization, Alliance Rejig; 40 Billion Yen Japan Sales Likely in 2020
December 11, 2020
-
BUSINESS Aducanumab Submitted in Japan, but Decision Unlikely to Come Until Next Autumn
December 11, 2020
-
BUSINESS Biogen Files Japan NDA for Aducanumab
December 10, 2020
-
REGULATORY Chuikyo Healthcare Reps Urge Minimal Scope for Off-Year Re-Pricing, Payers Grumble over Generic-Heavy Coverage
December 10, 2020
-
BUSINESS Takeda Aiming for Sales of 5 Trillion Yen by FY2030, Sees It Realistic Target with Strong Pipeline
December 10, 2020
-
REGULATORY MHLW Estimates: Off-Year Re-Pricing with Average Price Gap Threshold Likely to Hit 8,700 Products, Save 360 Billion Yen
December 9, 2020
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…